Clinical Trial Update: Bioequivalence Study For 5 Mg Amlodipine Orally-Disintegrating Tablet [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study evaluating a 5 mg amlodipine orally-disintegrating tablet completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthy

Drugs mentioned

• Amlodipine (amlodipine)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Healthy | Phase 1 | Status: COMPLETED | Results posted: 2012-01-04